New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Terminated
This early-phase study tests a new drug called JSI-1187, alone or with another drug (dabrafenib), in adults with advanced solid tumors that have certain gene changes (MAPK pathway mutations). The main goal is to check safety and find the right dose. About 71 people will take part…
Phase: PHASE1 • Sponsor: JS InnoPharm, LLC • Aim: Disease control
Last updated May 07, 2026 18:41 UTC